Novel Selection Process Leads to Improved Aptamers for HER2-Positive Cancer
Recently Belgian researchers showed that a combination of, next-generation sequencing, a novel method termed “Dubbles”, and TriLink’s 40 nucleotide random library led to the identification of potent aptamers that may provide new diagnostic and therapeutic avenues for patients with human epidermal growth factor receptor (HER2) positive breast cancer.
The research led by Marlies Gijs, from the Belgian Nuclear Research Centre, was published last month in Pharmaceuticals.
HER2 is a growth promoting transmembrane protein that is overexpressed in approximately 15-20% of breast cancers and is associated with poor patient prognosis. Current standard of care often includes trastuzumab, a humanized monoclonal antibody targeting the HER2 protein....